Even with modern antiretroviral therapy (ART) suppressing viral replication to undetectable levels, HIV leaves a lasting imprint on the body. Chronic, low-grade inflammation persists in most treated individuals and drives an array of health problems that increasingly resemble aging-related diseases: heart disease, bone thinning, kidney decline, liver scarring, cognitive changes, and elevated cancer risk. These effects accumulate over years and decades, making long-term HIV management far more than just keeping viral load in check.
The Engine Behind It All: Persistent Inflammation
The single most important concept for understanding why HIV causes long-term damage is chronic immune activation. Even when ART brings viral load to undetectable levels, the immune system does not fully stand down. A residual inflammatory state persists, marked by elevated inflammatory molecules in the blood and immune cells that remain switched on and eventually become exhausted. This ongoing activation is strongly linked to disease progression and CD4 T-cell loss even in successfully treated patients.1PubMed Central. Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection2PubMed Central. HIV-associated chronic immune activation
Part of what fuels this inflammation is damage to the gut lining. HIV attacks immune cells concentrated in the intestinal wall early in infection, and that barrier never fully heals. The result is that bacterial fragments leak from the gut into the bloodstream, a process called microbial translocation. Those fragments continuously prod the immune system, contributing to a background level of inflammation that raises the risk of complications throughout the body and even predicts mortality.3PubMed Central. Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV This persistent inflammatory state is the thread that connects most of the long-term effects described below.
Heart and Blood Vessel Disease
Cardiovascular disease has become one of the leading causes of serious illness in people aging with HIV. Elevated levels of C-reactive protein, activated inflammatory molecules, and other markers of vascular inflammation are common and contribute to damage to blood vessel walls, clotting abnormalities, and faster buildup of arterial plaque.4PubMed Central. Cardiovascular Disease in HIV Patients: A Comprehensive Review of Current Knowledge and Clinical Implications Early research assumed that traditional risk factors like smoking or high cholesterol, along with side effects from older antiretroviral drugs, explained most of the excess heart disease risk. More recent work points to chronic inflammation itself as a major independent driver. Inflammatory biomarkers have been tied to both clinical cardiovascular events and early, subclinical coronary artery disease in people living with HIV.5PubMed Central. Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer
The clinical picture has shifted as well. Rather than dramatic acute events early in life, cardiovascular disease in people with HIV tends to develop more gradually, with chronic and sometimes subtle presentations. That makes screening and proactive management of blood pressure, cholesterol, and blood sugar especially important for this population.
Brain and Cognitive Health
HIV can affect the brain even when viral load is well controlled. People who have been on ART for 15 years or longer score lower than HIV-negative peers in attention, working memory, motor function, and information processing speed, and they report more day-to-day cognitive difficulties.6PubMed Central. Neurocognitive Dysfunction With Neuronal Injury in People With HIV on Long-Duration Antiretroviral Therapy Brain imaging in those individuals shows reduced volume in deep brain structures, and spinal fluid contains elevated levels of neurofilament light chain, a marker of nerve cell injury, along with higher levels of the inflammatory molecule TNF-alpha.7PubMed Central. Neurocognitive Dysfunction With Neuronal Injury in People With HIV on Long-Duration Antiretroviral Therapy
An interesting finding from a 12-year follow-up study complicates the picture. Researchers expected that older age would predict faster cognitive decline, but it did not. Instead, the strongest predictors of worsening cognition were comorbid conditions: diabetes, high blood pressure, chronic lung disease, frailty, neuropathic pain, depression, and a history of cannabis use disorder. HIV disease severity and treatment characteristics were not significant predictors.8Brain. Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study The practical takeaway is that managing these comorbidities aggressively may protect cognitive function more than any HIV-specific intervention beyond ART itself.
Accelerated Biological Aging
One of the more striking long-term findings is that HIV appears to speed up biological aging at the cellular level. Epigenetic clocks, which estimate biological age by measuring chemical modifications to DNA, generally indicate that people living with HIV are roughly five to seven years biologically older than HIV-negative individuals of the same chronological age.9PubMed. Epigenetic clocks and accelerated biological aging in people living with HIV: Emerging mechanisms and clinical implications
A longitudinal study tracking epigenetic aging over time found that each year of untreated HIV infection added roughly 0.4 to 0.7 extra years of biological age, depending on which clock was used. ART partially reverses this: during suppressive treatment, the aging rate slowed and even dipped slightly below normal, suggesting some recovery. Still, years of untreated infection leave a lasting epigenetic footprint.10The Lancet HIV. Long-term epigenetic ageing dynamics in treated and untreated HIV infection: a longitudinal study The mechanisms behind this accelerated aging involve persistent viral activity, immune activation, oxidative stress, mitochondrial dysfunction, and the de-repression of mobile genetic elements within the human genome that can destabilize DNA.11PubMed Central. Epigenetic aging is a hallmark of HIV pathogenesis and phenotypic outcomes
Bone Loss and Fracture Risk
Low bone mineral density is far more common in people living with HIV than in the general population. A meta-analysis of cross-sectional studies found that the odds of osteoporosis were about 3.7 times higher in HIV-positive individuals compared with uninfected controls, and the prevalence of reduced bone density ranged widely across studies. Fracture risk is also elevated, with one pooled estimate putting the fracture rate at roughly 1.6 times higher than in HIV-negative people.12PubMed Central. Bone loss in HIV—a contemporary review
In a study of midlife women in Zimbabwe, osteoporosis at the hip and spine was several times more common in women living with HIV, and prior fractures were about twice as prevalent. Low weight, older age, and HIV infection itself were each independently linked to lower bone density.13Journal of Bone and Mineral Research. Prevalence of HIV-associated osteoporosis and fracture risk in midlife women: a cross-sectional study in Zimbabwe The causes are multifactorial: chronic inflammation erodes bone, some antiretroviral drugs (particularly tenofovir disoproxil fumarate) accelerate early bone loss after treatment initiation, and hormonal changes can compound the problem. Regular bone density screening and attention to calcium, vitamin D, and weight-bearing exercise matter more for people with HIV than for the average person.
Kidney and Liver Health
Chronic kidney disease occurs in a wide range of HIV-positive individuals, with prevalence estimates spanning from about 4% to nearly 50% depending on the population studied and the definitions used.14PubMed Central. HIV and chronic kidney disease HIV itself damages the kidneys, but so do some of the drugs used to treat it. Longer cumulative exposure to tenofovir and certain protease inhibitors is associated with a measurably higher rate of kidney function decline.15AIDS. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients Advanced HIV disease, low CD4 nadir, and older age amplify that risk.16PubMed Central. Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia Newer formulations of tenofovir (tenofovir alafenamide) were developed in part to reduce kidney and bone toxicity, but routine monitoring of kidney function remains standard practice for anyone on long-term ART.
The liver faces its own threats. Even in people with HIV alone, without hepatitis B or C co-infection, fatty liver disease is common and progressing. In one cohort, about 35% of people on long-term ART had liver steatosis (fat accumulation), and 9% had measurable fibrosis (scarring).17PubMed Central. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy The metabolic syndrome so frequently seen in treated HIV, including central obesity, insulin resistance, and abnormal cholesterol, feeds directly into liver disease. Weight gain and metabolic dysfunction-associated fatty liver disease are strong predictors of fibrosis progression.18PubMed Central. The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV Over eight years, people with HIV who had fatty liver disease at baseline were roughly three times more likely to develop clinically significant fibrosis than those without it.19PubMed Central. Metabolic dysfunction-associated liver disease predicts incident liver fibrosis in people with HIV mono-infection: A cohort study
Cancer Risk Beyond the Classic HIV-Related Cancers
In the early years of the epidemic, cancers directly tied to severe immune suppression, such as Kaposi sarcoma and certain lymphomas, were the primary concern. With ART dramatically improving survival, a different pattern has emerged: non-AIDS-defining cancers are now a growing cause of illness in people living with HIV.20eClinicalMedicine. Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis A long-term cohort study in Asia found that the 10-year cumulative incidence of these cancers was about 6%, with liver, colon, and stomach cancers occurring at rates several times higher than in the general population of the same age and sex.21PubMed Central. Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study A troubling feature of these cancers is that about half were diagnosed at an advanced stage, often in people between ages 40 and 59, younger than the typical cancer patient. Chronic inflammation, immune dysfunction, and co-infections like hepatitis all contribute to this elevated risk and underscore the value of age-appropriate cancer screening in this population.
Metabolic Disruption and Body Composition Changes
Metabolic complications have shadowed HIV treatment since the early days of ART. Lipodystrophy, a syndrome involving abnormal redistribution of body fat, was one of the first widely recognized long-term side effects. People with HIV-associated lipodystrophy often develop insulin resistance, abnormal blood lipids, and increased rates of diabetes and fatty liver disease.22HIV/AIDS – Research and Palliative Care. Biological Depiction of Lipodystrophy and Its Associated Challenges Among HIV AIDS Patients: Literature Review Metformin, a widely used diabetes drug, has shown benefit in randomized trials for reducing insulin levels, weight, and visceral fat in people with this condition.23JAMA. Metformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial
Newer antiretroviral drugs bring their own metabolic wrinkle. Integrase inhibitors, now the backbone of most first-line regimens, are associated with weight gain, particularly in the first two years of use. In a large observational cohort, people starting integrase inhibitor-based regimens gained an estimated 5.9 kg over five years on average, with dolutegravir linked to the most weight gain at about 7.2 kg over two years. Women and people with lower starting CD4 counts had higher odds of gaining more than 10% of body weight.24PubMed Central. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada The weight gain appears to plateau after about two years of use.25PubMed Central. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE) Since excess weight feeds into cardiovascular risk, liver disease, and diabetes, managing it has become a practical priority for many people on long-term treatment.
Mental Health and Quality of Life
Depression and anxiety are substantially more common among people with HIV than in the general population, and they do not always resolve once viral load is suppressed. In one cross-sectional study at Ethiopian ART clinics, about 38% of participants had depression and about 32% had anxiety. Being female, having a higher viral load, and having a very low CD4 count were associated with depression, while the antiretroviral drug efavirenz and female sex were linked to anxiety.26The Open AIDS Journal. Anxiety and Depression Disorder among Adult People Living with HIV/AIDS on Follow-up at Dessie Public Health Facilities Antiretroviral Therapy Clinics, Northeast Ethiopia: A Multicenter Cross-sectional Study These are not just quality-of-life concerns. A prospective study in Uganda found that people who entered treatment with significant depression or anxiety continued to have meaningfully worse quality of life 18 months later, even as their immune health improved. The disadvantage was dose-dependent: the worse the depression or anxiety at baseline, the less quality-of-life improvement ART delivered.27PubMed Central. Depressive and Anxiety Symptoms Predict Sustained Quality of Life Deficits in HIV-Positive Ugandan Adults Despite Antiretroviral Therapy A Prospective Cohort Study Screening for and treating mental health conditions should be as routine as checking viral load.
Frailty and Physical Function
Frailty, a state of increased vulnerability to physical stressors, develops earlier and more frequently in people with HIV. In a study of older HIV-positive adults, about 15% met clinical criteria for frailty and over half were classified as pre-frail. More than half had meaningful functional impairment on standard physical performance tests, and about one in five had a slow walking speed.28Age and Ageing. Frailty and physical function in older HIV-infected adults All participants in that study could still walk independently and perform basic daily activities, so frailty here refers to a measurable decline in reserve capacity rather than outright disability. Exercise interventions, fall prevention, and nutritional support are increasingly part of HIV care as the treated population ages.
Reproductive and Hormonal Effects
Women living with HIV appear to reach menopause earlier than their HIV-negative peers. A systematic review found that five of seven studies reported an earlier menopausal transition in women with HIV, and all six studies examining premature ovarian insufficiency or early menopause found a higher prevalence among HIV-positive women.29Menopause. Age at menopause in women living with HIV: a systematic review In a large U.S. cohort, about 1% of women experienced menopause before age 41 and another 3% between ages 41 and 45.30PubMed Central. Premature and early menopause among US women with or at risk for HIV Earlier menopause compounds other long-term effects of HIV: it accelerates bone loss, increases cardiovascular risk, and can worsen mood symptoms at a younger age than expected. Many women affected are not receiving hormone therapy.31PubMed Central. Premature and early menopause among US women with or at risk for HIV
Why the Virus Never Truly Leaves
A persistent puzzle for researchers and a source of frustration for patients is that HIV is never fully eliminated by current treatments. The virus inserts its genetic material into long-lived cells, creating reservoirs that can reignite infection the moment therapy is stopped.32PubMed. HIV persistence: silence or resistance? These reservoirs are not limited to the blood. Studies of tissue samples from people on long-term ART have detected HIV DNA scattered throughout deep tissues, with viral levels varying widely from site to site.33JCI Insight. HIV persists throughout deep tissues with repopulation from multiple anatomical sources This widespread tissue presence helps explain why inflammation does not fully resolve on treatment: even at low levels, viral proteins and DNA fragments keep the immune system on alert. Cure research is pursuing strategies to either flush out these reservoirs or permanently silence them, but for now, lifelong ART remains necessary.
Vaccine Responses Over Time
People living with HIV tend to lose vaccine-induced protection faster than the general population. A systematic review and meta-analysis of routinely recommended vaccines found that seroprotection waned more quickly in HIV-positive individuals, meaning that a substantial proportion lost protective antibody levels before a booster dose was scheduled under standard guidelines.34PubMed Central. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis This is relevant for hepatitis B, influenza, pneumococcal vaccines, and others. It also reinforces the importance of checking antibody levels rather than simply assuming protection after vaccination, and of being prepared for more frequent boosters.
Sleep Disruption and Its Consequences
Poor sleep is remarkably common among people with HIV and has downstream effects that go beyond tiredness. In one study, over a third of participants had sleep patterns consistent with chronic partial sleep deprivation, and those individuals performed worse on tests of processing speed, fine motor control, and verbal fluency.35JAIDS Journal of Acquired Immune Deficiency Syndromes. Evaluating Sleep and Cognition in HIV Sleep disturbance can amplify inflammation, worsen metabolic health, and deepen depression, all of which are already elevated risks in this population. Treating sleep problems may therefore have outsized benefits for people living with HIV, though it is one of the more overlooked aspects of long-term care.
Growing Up with HIV: Perinatally Infected Young Adults
A unique population now reaching adulthood consists of people who acquired HIV at or before birth and have been living with the virus their entire lives. Their long-term health profile is concerning. By age 30, cumulative incidence rates of chronic diseases in one North American cohort were striking: roughly 50% for high triglycerides, 40% for high cholesterol, 25% for chronic kidney disease, about 22% for high blood pressure, and 19% for type 2 diabetes.36PubMed Central. Incidence of non-AIDS defining comorbidities among young adults with perinatally-acquired HIV in North America, 2000–2019 These are rates you would expect in a much older population.
Immunologically, young adults with perinatal HIV show higher levels of exhausted and senescent immune cells, shorter telomeres, reduced new T-cell production from the thymus, and elevated inflammatory markers compared with HIV-negative peers.37PLoS Pathogens. HIV reservoir and premature aging: risk factors for aging-associated illnesses in adolescents and young adults with perinatally acquired HIV There is also early evidence of increased mental health burden, including a reported six-fold higher prevalence of psychosis compared to age-matched peers without HIV.38PubMed Central. Aging of adult lifetime survivors with perinatal HIV As this first generation of lifelong survivors moves into middle age, their care needs will increasingly test health systems that were designed around HIV as an adult-onset infection.